BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 22343920)

  • 1. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
    Damm F; Kosmider O; Gelsi-Boyer V; Renneville A; Carbuccia N; Hidalgo-Curtis C; Della Valle V; Couronné L; Scourzic L; Chesnais V; Guerci-Bresler A; Slama B; Beyne-Rauzy O; Schmidt-Tanguy A; Stamatoullas-Bastard A; Dreyfus F; Prébet T; de Botton S; Vey N; Morgan MA; Cross NC; Preudhomme C; Birnbaum D; Bernard OA; Fontenay M;
    Blood; 2012 Apr; 119(14):3211-8. PubMed ID: 22343920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.
    Makishima H; Visconte V; Sakaguchi H; Jankowska AM; Abu Kar S; Jerez A; Przychodzen B; Bupathi M; Guinta K; Afable MG; Sekeres MA; Padgett RA; Tiu RV; Maciejewski JP
    Blood; 2012 Apr; 119(14):3203-10. PubMed ID: 22323480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
    BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.
    Patnaik MM; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Pardanani A; Tefferi A
    Am J Hematol; 2013 Mar; 88(3):201-6. PubMed ID: 23335386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
    Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
    Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling.
    Taskesen E; Havermans M; van Lom K; Sanders MA; van Norden Y; Bindels E; Hoogenboezem R; Reinders MJ; Figueroa ME; Valk PJ; Löwenberg B; Melnick A; Delwel R
    Blood; 2014 May; 123(21):3327-35. PubMed ID: 24668493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS: A meta-analysis.
    Wang X; Song X; Yan X
    Medicine (Baltimore); 2019 May; 98(21):e15743. PubMed ID: 31124956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
    Sallman DA; Komrokji R; Vaupel C; Cluzeau T; Geyer SM; McGraw KL; Al Ali NH; Lancet J; McGinniss MJ; Nahas S; Smith AE; Kulasekararaj A; Mufti G; List A; Hall J; Padron E
    Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors.
    Je EM; Yoo NJ; Kim YJ; Kim MS; Lee SH
    Int J Cancer; 2013 Jul; 133(1):260-5. PubMed ID: 23280334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
    Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
    Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Splicing Factor Mutations in Cancer.
    Bejar R
    Adv Exp Med Biol; 2016; 907():215-28. PubMed ID: 27256388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration of the SETBP1 gene and splicing pathway genes SF3B1, U2AF1, and SRSF2 in childhood acute myeloid leukemia.
    Choi HW; Kim HR; Baek HJ; Kook H; Cho D; Shin JH; Suh SP; Ryang DW; Shin MG
    Ann Lab Med; 2015 Jan; 35(1):118-22. PubMed ID: 25553291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.
    Wu L; Song L; Xu L; Chang C; Xu F; Wu D; He Q; Su J; Zhou L; Xiao C; Zhang Z; Zhao Y; Chen S; Li X
    Tumour Biol; 2016 Apr; 37(4):4633-40. PubMed ID: 26508027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mutational analysis of RNA splicing machinery genes SF3B1, U2AF1 and SRSF2 in 118 patients with myelodysplastic syndromes and related diseases].
    Wang JY; Ma J; Lin YN; Wang J; Shen H; Gui FM; Han C; Li QH; Song Z; Wang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):192-197. PubMed ID: 28395441
    [No Abstract]   [Full Text] [Related]  

  • 15. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML.
    Hirabayashi S; Flotho C; Moetter J; Heuser M; Hasle H; Gruhn B; Klingebiel T; Thol F; Schlegelberger B; Baumann I; Strahm B; Stary J; Locatelli F; Zecca M; Bergstraesser E; Dworzak M; van den Heuvel-Eibrink MM; De Moerloose B; Ogawa S; Niemeyer CM; Wlodarski MW;
    Blood; 2012 Mar; 119(11):e96-9. PubMed ID: 22238327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
    Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
    Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Deregulated splicing machinery in myelodysplastic syndromes].
    Ogawa S
    Rinsho Ketsueki; 2012 May; 53(5):493-6. PubMed ID: 22728550
    [No Abstract]   [Full Text] [Related]  

  • 18. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome.
    Mian SA; Smith AE; Kulasekararaj AG; Kizilors A; Mohamedali AM; Lea NC; Mitsopoulos K; Ford K; Nasser E; Seidl T; Mufti GJ
    Haematologica; 2013 Jul; 98(7):1058-66. PubMed ID: 23300180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand.
    Yimpak P; Tantiworawit A; Rattanathammethee T; Angsuchawan S; Laowatthanapong S; Tasuya W; Bumroongkit K
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1215-1221. PubMed ID: 31030497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia.
    Hou HA; Liu CY; Kuo YY; Chou WC; Tsai CH; Lin CC; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Tien HF
    Oncotarget; 2016 Feb; 7(8):9084-101. PubMed ID: 26812887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.